| Filed On | Filing |
|---|---|
| 08 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On September 1, 2026, Estrella Immunopharma, Inc. (the “Company”) received a written notification (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the market val... |
| 26 Aug 2026 |
Form 4: Liu Cheng, Director
Received 100,000 shares by exercise or conversion ($81.5K) · Acquired 100,000 Incentive Stock Option (Option Exercise/Conversion) |
| 25 Aug 2026 |
Form 4: Xu Jiandong, Chief Financial Officer
Received 100,000 shares by exercise or conversion ($81.5K) |
| 21 Aug 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | QUARTERLY REPORT |
| 30 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 27 May 2026 | Proxy statement: annual meeting on June 29, 2026 |
| 18 May 2026 | NOTIFICATION OF LATE FILING |
| 18 May 2026 | QUARTERLY REPORT |
| 15 May 2026 | SCHEDULE 13G |
| 30 Apr 2026 | AMENDMENT NO. 1 TO FORM 10-K |
| 29 Apr 2026 |
Form 4: Xu Jiandong, Chief Financial Officer
Bought 100 shares ($104) · Bought 1,000 shares ($1.16K) · Bought 1,000 shares ($1.33K) |
| 18 Mar 2026 | ANNUAL REPORT |
| 13 Feb 2026 | PROSPECTUS |
| 23 Jan 2026 | EFFECT |
| 22 Jan 2026 | CORRESP |
| 22 Jan 2026 | REGISTRATION STATEMENT |
| 16 Jan 2026 | REGISTRATION STATEMENT |
| 13 Jan 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
Loading...
